BVAXF.US Biovaxys Technology Corp
- Market cap
- USD 3.62M
- P/E
- -
- P/B
- 8.86x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Apr 2025.
Is BVAXF.US undervalued?
Graham numberThe Graham number of Biovaxys Technology Corp cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Biovaxys Technology Corp fundamental analysis
No fundamental analysis for Biovaxys Technology Corp yet.
Biovaxys Technology Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Biovaxys Technology Corp
BioVaxys Technology Corp., a clinical-stage biotechnology company, engages in developing viral and oncology vaccine platforms and immuno-diagnostics. The company offers DPX immune educating technology platform and HapTenix neoantigen tumor cell construct platform for treating cancers, infectious diseases, antigen desensitization, and other immune diseases. It also provides Maveropepimut-S (MVP-S), which has completed phase IIb clinical trial for advanced Relapsed-Refractory …
Full company profileBiovaxys Technology Corp financial statements
2025 annualized: Fiscal year 2025 is not finished. Income statement and cash flow are annualized from 2 quarters up to Apr 30, 2025, the balance sheet is the latest quarter. Figures change when the annual report is published.
Biovaxys Technology Corp annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -230K | -1.10M | -6.44M | -4.08M | -6.45M | -3.30M | -4.99M |
| EBITDA | -230K | -1.09M | -6.42M | 3.58M | -6.45M | -3.30M | -4.99M |
| Net Income | -230K | -1.17M | -6.46M | -11.7M | -7.69M | -3.95M | -4.77M |
| EPS | -0.01 | -0.02 | -0.08 | -0.12 | -0.53 | -0.15 | -0.16 |
| Balance Sheet | |||||||
| Total Assets | 306K | 10.5M | 8.50M | 866K | 113K | 1.30M | 1.10M |
| Total Liabilities | 116K | 900K | 327K | 1.64M | 3.49M | 3.22M | 3.83M |
| Shareholders' Equity | 190K | 9.56M | 8.18M | -774K | -3.37M | -1.92M | -2.73M |
| Cash & Short-term Investments | 229K | 2.42M | 593K | 142K | 977.00 | 212K | 4.31K |
| Cash Flow | |||||||
| Operating Cash Flow | -231K | -1.23M | -5.29M | -1.57M | -1.05M | -1.86M | -1.80M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.06M | 0.00 |
| Free Cash Flow | -231K | -1.23M | -5.29M | -1.57M | -1.05M | -2.92M | -3.91M |
| Ratios | |||||||
| ROE | -121.0% | -12.3% | -79.0% | - | - | - | - |
| ROA | -75.1% | -11.2% | -75.9% | -1,354.9% | -6,774.3% | -304.0% | -433.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
Biovaxys Technology Corp dividends
Biovaxys Technology Corp has not paid dividends in the last 6 fiscal years.
Last stock split: 1:10 on Sep 11, 2025.
Who owns Biovaxys Technology Corp
- Insiders 8.23%
- Institutions 0.00%
- Public & others 91.77%
- Shares outstanding 40.7M
- Free float 26.1M
Biovaxys Technology Corp company profile
- Company name
- Biovaxys Technology Corp
- Ticker
- BVAXF.US
- ISIN
- CA09076M1014
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- October
- Address
- 146 Thirtieth Street, Etobicoke, ON, Canada, M8W 3D4
- Phone
- 740-358-0555
- Website
- biovaxys.com
About Biovaxys Technology Corp
BioVaxys Technology Corp., a clinical-stage biotechnology company, engages in developing viral and oncology vaccine platforms and immuno-diagnostics. The company offers DPX immune educating technology platform and HapTenix neoantigen tumor cell construct platform for treating cancers, infectious diseases, antigen desensitization, and other immune diseases. It also provides Maveropepimut-S (MVP-S), which has completed phase IIb clinical trial for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma and for platinum resistant ovarian cancer; MVP-S +1 Keytruda that is in IIb clinical trial to treat lung cancer, bladder cancer, liver cancer, DLBCL, and ovarian cancer subpopulations; BVX-0918, a haptenized tumor cell vaccine for ovarian cancer; and DPX SurMAGE, a formulation of the tumor-associated antigens survivin and MAGE A9 as a dual targeted immunotherapy. In addition, the company develops DPX-RSV that is in phase II clinical stage for Respiratory Syncytial Virus; DPX-Flu, which is in phase I clinical stage used to treat multiple strains of influenza; DPX-Neo, which is in phase I trial used for evaluating UConn Health's proprietary neoepitopes; DPX-E7 to evaluate changes in CD8+ T cells in peripheral blood and tumor tissue and evaluate the safety in HLA-A2positive patients; and DPX-rPA anthrax vaccine. Further, the company operates HapTenix Platform, a vaccine platform based on the established immunological concept that modifies surface proteins with haptens and T-Cell Antigen Discovery Program. It has agreement with AP Visionaries, Inc. to develop a proprietary DPX formulation for alleviate the potentially life-threatening risk of certain food allergies triggered by exposure to peanut/tree nuts or eggs and Adiverna LLC to develop mRNA-based Rabies, Leptospirosis, Feline Infectious Peritonitis (FIV) and other mRNA-based vaccines for companion animal veterinary applications. BioVaxys Technology Corp. is headquartered in Etobicoke, Canada.
Biovaxys Technology Corp management
4- Mr. James Christopher PassinCo-Founder, CEO, & Director · born 1972
- Mr. Kenneth E. KovanCo-Founder, President & COO · born 1962
- Mr. Christopher P. CherryChief Financial Officer
- Dr. David Berd M.D.Co-Founder & Chief Medical Officer · born 1943